A year ago, if someone had told Dr (Col) V K Gupta, 64, that he would not just be declared “free of cancer cells” — despite a failed bone marrow transplant in 2022 — but would be able to get back to work in 2024, he would have brushed it off as polite optimism.Months after India’s drug regulator approved the commercial use of CAR-T cell therapy, a pioneering treatment that genetically reprogrammes a patient’s immune system to fight cancer, Gupta, a Delhi-based gastroenterologist, became one of t...